Chemotherapy for ovarian cancer.
10.5124/jkma.2016.59.3.175
- Author:
Myong Cheol LIM
1
;
Sang Yoon PARK
Author Information
1. Center for Uterine Cancer and Gynecologic Cancer Branch, National Cancer Center, Goyang, Korea. parksang@ncc.re.kr
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Ovarian neoplasms;
Drug therapy;
Intraperitoneal chemotherapy;
Hyperthermic intraperitoneal chemotherapy
- MeSH:
Abdominal Pain;
Chemotherapy, Adjuvant;
Drug Therapy*;
Neoplasm, Residual;
Ovarian Neoplasms*;
Peritoneal Cavity
- From:Journal of the Korean Medical Association
2016;59(3):175-179
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The standard treatment for epithelial ovarian cancer is maximal cytoreductive surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy can be considered as an alternative treatment strategy when unacceptable primary surgery, in terms of gross residual tumor remaining at the end of cytoreduction, is expected or in cases where poor general condition renders extensive cytoreductive surgery unsuitable. Intraperitoneal chemotherapy is ideal for epithelial ovarian cancer because its spread is mainly limited to the peritoneal cavity. Several randomized controlled trials have reported a survival gain with intraperitoneal chemotherapy. However, disadvantages such as port-related complications, abdominal pain, and neurotoxicity hinder its wide use. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been suggested as an alternative treatment strategy for intraperitoneal chemotherapy. Ongoing clinical trials of hyperthermic intraperitoneal chemotherapy will quantify clinical outcomes in the future, such as the survival benefit in epithelial ovarian cancer.
